Reduced in vivo high-energy phosphates precede adriamycin-induced cardiac dysfunction

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 299, Issue 2, 2010, Pages

  Maslov, M Y ^a   Chacko, V P ^a   Hirsch, G A ^a   Akki, A ^a   Leppo, M K ^a   Steenbergen, C ^a   Weiss, R G ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

31P spectroscopy; Magnetic resonance imaging

Indexed keywords

ADENOSINE TRIPHOSPHATE; CREATINE PHOSPHATE; DOXORUBICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOMYOPATHY; CARDIOTOXICITY; CONTROLLED STUDY; HEART DISEASE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HIGH ENERGY PHOSPHATE; MALE; NONHUMAN; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; RAT;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; DISEASE MODELS, ANIMAL; DOWN-REGULATION; DOXORUBICIN; ENERGY METABOLISM; MAGNETIC RESONANCE IMAGING, CINE; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; MICE, INBRED C57BL; MYOCARDIAL CONTRACTION; MYOCARDIUM; PHOSPHOCREATINE; STROKE VOLUME; TIME FACTORS; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 77955442081     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00727.2009     Document Type: Article

References (48)

1. 31P NMR data (Abstract). Soc Magn Res Med 9: 1089, 1990.
2. Billingham ME, Mason JW, Bristow MR, Daniels JR. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 62: 865-872, 1978.
3. Bottomley PA, Hardy CJ, Roemer PB, Weiss RG. Problems and expediencies in human 31P spectroscopy. The definition of localized volumes, dealing with saturation and the technique-dependence of quantification. NMR Biomed 2: 284-289, 1989.
4. Brdiczka DG, Zorov DB, Sheu SS. Mitochondrial contact sites: their role in energy metabolism and apoptosis. Biochim Biophys Acta 1762: 148-163, 2006.
5. Bruynzeel AM, Vormer-Bonne S, Bast A, Niessen HW, van der Vijgh WJ. Long-term effects of 7-monohydroxyethylrutoside (monoHER) on DOX-induced cardiotoxicity in mice. Cancer Chemother Pharmacol 60: 509-514, 2007. (Pubitemid 47084261)
6. Buja LM, Ferrans VJ, Mayer RJ, Roberts WC, Henderson ES. Cardiac ultrastructural changes induced by daunorubicin therapy. Cancer 32: 771-788, 1973.
7. Chacko VP, Aresta F, Chacko SM, Weiss RG. MRI/MRS assessment of in vivo murine cardiac metabolism, morphology, and function at physiological heart rates. Am J Physiol Heart Circ Physiol 279: H2218-H2224, 2000.
8. Dekker T, van Echteld CJ, Kirkels JH, Ruigrok TJ, van Hoesel QG, de Jong WH, Schornagel JH. Chronic cardiotoxicity of adriamycin studied in a rat model by 31P NMR. NMR Biomed 4: 16-24, 1991.
9. Delgado RM 3rd, Nawar MA, Zewail AM, Kar B, Vaughn WK, Wu KK, Aleksic N, Sivasubramanian N, McKay K, Mann DL, Willerson JT. Cyclooxygenase-2 inhibitor treatment improves left ventricular function and mortality in a murine model of doxorubicin-induced heart failure. Circulation 109: 1428-1433, 2004.
10. Doroshow JH, Locker GY, Ifrim I, Myers CE. Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine. J Clin Invest 68: 1053-1064, 1981.
11. Eidenschink AB, Schröter G, Müller-Weihrich S, Stern H. Myocardial high-energy phosphate metabolism is altered after treatment with anthracycline in childhood. Cardiol Young 10: 610-617, 2000.
12. Eliot H, Gianni L, Myers C. Oxidative destruction of DNA by the adriamycin-iron complex. Biochemistry 23: 928-936, 1984.
13. Hamman BL, Bittl JA, Jacobus WE, Allen PD, Spencer RS, Tian R, Ingwall JS. Inhibition of the creatine kinase reaction decreases the contractile reserve of isolated rat hearts. Am J Physiol Heart Circ Physiol 269: H1030-H1036, 1995.
14. Hardy CJ, Weiss RG, Bottomley PA, Gerstenblith G. Altered myocardial high-energy phosphate metabolites in patients with dilated cardiomyopathy. Am Heart J 122: 795-801, 1991.
15. Ingwall JS, Kramer MF, Fifer MA, Lorell BH, Shemin R, Grossman W, Allen PD. The creatine kinase system in normal and diseased human myocardium. N Engl J Med 313: 1050-1054, 1985.
16. Ito H, Miller SC, Billingham ME, Akimoto H, Torti SV, Wade R, Gahlmann R, Lyons G, Kedes L, Torti FM. Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro. Proc Natl Acad Sci USA 87: 4275-4279, 1990.
17. Lefrak EA, Pitha J, Rosenheim S, Gottleib JA. A clinicopathologic analysis of ADR cardiotoxicity. Cancer 32: 302-314, 1973.
18. Lenaz L, Page JA. Cardiotoxicity of adriamycin and related anthracyclines. Cancer Treat Rev 3: 111-120, 1976.
19. Maslov MY, Chacko VP, Stuber M, Moens AL, Kass DA, Champion HC, Weiss RG. Altered high-energy phosphate metabolism predicts contractile dysfunction and subsequent ventricular remodeling in pressure-overload hypertrophy mice. Am J Physiol Heart Circ Physiol 292: H387-H391, 2007.
20. Mihm MJ, Yu F, Weinstein DM, Reiser PJ, Bauer JA. Intracellular distribution of peroxynitrite during doxorubicin cardiomyopathy: evidence for selective impairment of myofibrillar creatine kinase. Br J Pharmacol 135: 581-588, 2002.
21. Mingyan E, Hongli L, Shufeng L, Bo Y. Effects of pyrrolidine dithiocarbamate on antioxidant enzymes in cardiomyopathy induced by adriamycin in rats. Cardiology 111: 119-125, 2008.
22. Miura T, Muraoka S, Fujimoto Y. Inactivation of creatine kinase by Adriamycin during interaction with horseradish peroxidase. Biochem Pharmacol 60: 95-99, 2000.
23. 31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered cardiac high-energy phosphate metabolism in heart failure. Circulation 86: 1810-1818, 1992.
24. 31P-NMR and implications for adriamycininduced cardiotoxicity. Biochim Biophys Acta 929: 5-13, 1987.
25. Praga C, Beretta G, Vigo PL, Lenaz GR, Pollini C, Bonadonna G, Canetta R. Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat Rep 63: 827-834, 1979.
26. Sakaguchi H, Kodama A, Tomonari M, Ando Y, Tabuchi M, To H, Araki R, Kitahara T, Sasaki H, Ohdo S, Higuchi S. Pre-administration of docetaxel protects against adriamycin-induced cardiotoxicity. Breast Cancer Res Treat 109: 443-450, 2008.
27. Saks VA, Kuznetsov AV, Kupriyanov VV, Miceli MV, Jacobus WE. Creatine kinase of rat heart mitochondria. The demonstration of functional coupling to oxidative phosphorylation in an inner membrane-matrix preparation. J Biol Chem 260: 7757-7764, 1985.
28. Schlattner U, Wallimann T. Metabolite channeling: creatine kinase microcompartments. In: Encyclopedia of Biological Chemistry, ed. by Lennarz WJ. New York: Academic, 2004, p. 646-651.
29. Seraydarian MW, Artaza L, Goodman MF. Adriamycin: effect on mammalian cardiac cells in culture. I. Cell population and energy metabolism. J Mol Cell Cardiol 9: 375-382, 1977.
30. Shen W, Spindler M, Higgins MA, Jin N, Gill RM, Bloem LJ, Ryan TP, Ingwall JS. The fall in creatine levels and creatine kinase isozyme changes in the failing heart are reversible: complex post-transcriptional regulation of the components of the CK system. J Mol Cell Cardiol 39: 537-544, 2005.
31. Sinha K, Chignell CF. Binding mode of chemically activated semiquinone free radicals from quinone anticancer agents to DNA. Chem Biol Interact 28: 301-308, 1979.
32. Smith CS, Bottomley PA, Schulman SP, Gerstenblith G, Weiss RG. Altered creatine kinase adenosine triphosphate kinetics in failing hypertrophied human myocardium. Circulation 114: 1151-1158, 2006.
33. Steinberg JS, Cohen AJ, Wasserman AG, Cohen P, Ross AM. Acute arrhythmogenicity of doxorubicin administration. Cancer 60: 1213-1238, 1987.
34. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266: 1672-1677, 1991.
35. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97: 2869-2879, 2003.
36. Takemura G, Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 49: 330-352, 2007.
37. Tian R, Ingwall JS. Energetic basis for reduced contractile reserve in isolated rat hearts. Am J Physiol Heart Circ Physiol 270: H1207-H1216, 1996.
38. Tokarska-Schlattner M, Wallimann T, Schlattner U. Multiple interference of anthracyclines with mitochondrial creatine kinases: preferential damage of the cardiac isoenzyme and its implications for drug cardiotoxicity. Mol Pharmacol 61: 516-523, 2002.
39. Tokarska-Schlattner M, Zaugg M, Zuppinger C, Wallimann T, Schlattner U. New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics. J Mol Cell Cardiol 41: 389-405, 2006.
40. Tolekis AI, Kal'venas AA, Dzheia PP, Prashkiavichius AK, Iasatis AA. Functional changes in the mitochondrial site of adenylate kinase and creatine kinase systems of energy transport induced by myocardial ischemia and adriablastin. Biokhimiia 53: 649-654, 1988.
41. van Acker SA, Voest EE, Beems DB, Madhuizen HT, de Jong J, Bast A, van der Vijgh WJ. Cardioprotective properties of O-(beta-hydroxyethyl)-rutosides in doxorubicin-pretreated BALB/c mice. Cancer Res 53: 4603-4607, 1993.
42. Vedam K, Nishijima Y, Druhan LJ, Khan M, Moldovan NI, Zweier JL, Ilangovan G. Role of heat-shock factor-1 activation in the doxorubicin-induced heart failure in mice. Am J Physiol Heart Circ Physiol 298: H1832-H1841, 2010.
43. Wallimann T, Kuhn HJ, Pelloni G, Turner DC, Eppenberger HM. Localization of creatine kinase isoenzymes in myofibrils. II. Chicken heart muscle. J Cell Biol 75: 318-325, 1977. (Pubitemid 8204987)
44. Wallimann T. Bioenergetics. Dissecting the role of creatine kinase. Curr Biol 4: 42-46, 1994.
45. Weinstein DM, Mihm MJ, Bauer JA. Cardiac peroxynitrite formation and left ventricular dysfunction following doxorubicin treatment in mice. J Pharmacol Exp Ther 294: 396-401, 2000.
46. Weiss RB. The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 19: 670-686, 1992.
47. Weiss RG, Gerstenblith G, Bottomley PA. ATP flux through creatine kinase in the normal, stressed, and failing human heart. Proc Natl Acad Sci USA 102: 808-813, 2005.
48. Williams RE, Kass DA, Kawagoe Y, Pak P, Tunin RS, Shah R, Hwang A, Feldman AM. Endomyocardial gene expression during development of pacing tachycardia-induced heart failure in the dog. Circ Res 75: 615-623, 1994.